CompoAtlas

Prostate Elixir

Prostate Elixir, licence 80109833: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Licence holder
Wide Naturals Inc.
NPN or DIN-HM
80109833
Status
Active licence
Licence date
11 May 2021
Revision date
Not provided
Form
Liquide
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Cannabis sativa

Source : Graine

83.3 mgNot calculated
Serenoa repens

Source : Fruit

Extract : Matériel brut sec

Extraction ratio : 4:1

Dry plant equivalent : 334 mg

83.5 mgNot calculated

Non-medicinal ingredients

Alcool éthylique, Eau

PopulationAgeQuantity per servingFrequency
Adultesminimum: 18.0 Année(s)1.0 mL3.0 Tous les jours

Uses authorised in Canada

Source of/Provides antioxidants. Source of/provides antioxidants that help fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Used in Herbal Medicine to help relieve urologic (e.g. weak urine flow/incomplete voiding/frequent daytime/night time urination) associated with mild to moderate benign prostatic hyperplasia (BPH).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80109833

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line